T. Rowe Price Associates’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-45,906
| Closed | -$432K | – | 2761 |
|
|
2020
Q3 | $432K | Sell |
45,906
-116
| -0.3% | -$1.1K | ﹤0.01% | 2149 |
|
|
2020
Q2 | $352K | Sell |
46,022
-4,009
| -8% | -$30.7K | ﹤0.01% | 2197 |
|
|
2020
Q1 | $309K | Buy |
50,031
+16,110
| +47% | +$142K | ﹤0.01% | 2181 |
|
|
2019
Q4 | $413K | Buy |
33,921
+1,335
| +4% | +$14.6K | ﹤0.01% | 2224 |
|
|
2019
Q3 | $376K | Buy |
32,586
+19,923
| +157% | +$210K | ﹤0.01% | 2208 |
|
|
2019
Q2 | $127K | Buy |
12,663
+100
| +0.8% | +$1.08K | ﹤0.01% | 2458 |
|
|
2019
Q1 | $162K | Sell |
12,563
-449,543
| -97% | -$6.69M | ﹤0.01% | 2428 |
|
|
2018
Q4 | $7.02M | Sell |
462,106
-6,076
| -1% | -$116K | ﹤0.01% | 1367 |
|
|
2018
Q3 | $9.36M | Buy |
468,182
+4,521
| +1% | +$103K | ﹤0.01% | 1386 |
|
|
2018
Q2 | $9.04M | Buy |
463,661
+196,249
| +73% | +$4.34M | ﹤0.01% | 1364 |
|
|
2018
Q1 | $5.39M | Buy |
267,412
+69,253
| +35% | +$1.17M | ﹤0.01% | 1422 |
|
|
2017
Q4 | $2.63M | Buy |
198,159
+1,573
| +0.8% | +$23.7K | ﹤0.01% | 1522 |
|
|
2017
Q3 | $3.63M | Sell |
196,586
-10,236
| -5% | -$191K | ﹤0.01% | 1475 |
|
|
2017
Q2 | $3.81M | Sell |
206,822
-11,898
| -5% | -$236K | ﹤0.01% | 1445 |
|
|
2017
Q1 | $4.93M | Buy |
218,720
+7,220
| +3% | +$173K | ﹤0.01% | 1432 |
|
|
2016
Q4 | $7.36M | Buy |
211,500
+9,310
| +5% | +$278K | ﹤0.01% | 1366 |
|
|
2016
Q3 | $4.96M | Sell |
202,190
-331,310
| -62% | -$8.28M | ﹤0.01% | 1429 |
|
|
2016
Q2 | $12.8M | Buy |
533,500
+13,120
| +3% | +$301K | ﹤0.01% | 1238 |
|
|
2016
Q1 | $12.2M | Sell |
520,380
-9,980
| -2% | -$237K | ﹤0.01% | 1226 |
|
|
2015
Q4 | $16M | Buy |
530,360
+22,800
| +4% | +$737K | ﹤0.01% | 1154 |
|
|
2015
Q3 | $20.2M | Buy |
507,560
+43,090
| +9% | +$2.67M | ﹤0.01% | 1086 |
|
|
2015
Q2 | $32.1M | Buy |
464,470
+27,200
| +6% | +$1.71M | 0.01% | 986 |
|
|
2015
Q1 | $23.9M | Buy |
437,270
+4,300
| +1% | +$205K | ﹤0.01% | 1072 |
|
|
2014
Q4 | $18.5M | Buy |
432,970
+6,850
| +2% | +$248K | ﹤0.01% | 1137 |
|
|
2014
Q3 | $13.6M | Buy |
426,120
+900
| +0.2% | +$19.2K | ﹤0.01% | 1222 |
|
|
2014
Q2 | $8.81M | Sell |
425,220
-995,900
| -70% | -$18.4M | ﹤0.01% | 1344 |
|
|
2014
Q1 | $27.5M | Sell |
1,421,120
-233,900
| -14% | -$4.97M | 0.01% | 1032 |
|
|
2013
Q4 | $40.2M | Sell |
1,655,020
-444,302
| -21% | -$10.4M | 0.01% | 905 |
|
|
2013
Q3 | $45.1M | Buy |
2,099,322
+59,922
| +3% | +$1.42M | 0.01% | 850 |
|
|
2013
Q2 | $45.4M | Buy |
+2,039,400
| New | +$44.9M | 0.01% | 823 |
|
T. Rowe Price Associates's AMAG Position: Q4 2020 in Review
T. Rowe Price Associates sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 45,906 shares — an estimated $432K sold.
T. Rowe Price Associates first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $45.4M in Q2 2013. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- T. Rowe Price Associates reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- T. Rowe Price Associates sold 45,906 AMAG Pharmaceuticals shares in Q4 2020, an estimated $432K.
- T. Rowe Price Associates first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- T. Rowe Price Associates's AMAG Pharmaceuticals position peaked at $45.4M in Q2 2013.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.